Review



cell free dna bct tubes  (Streck Laboratories)


Bioz Verified Symbol Streck Laboratories is a verified supplier
Bioz Manufacturer Symbol Streck Laboratories manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 98
      Buy from Supplier

    Structured Review

    Streck Laboratories cell free dna bct tubes
    Cell Free Dna Bct Tubes, supplied by Streck Laboratories, used in various techniques. Bioz Stars score: 98/100, based on 1543 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cell+free+dna+bct+tubes/Cell-Free+DNA+BCT/pm42355602-51-10-14
    Average 98 stars, based on 1543 article reviews
    cell free dna bct tubes - by Bioz Stars, 2026-10
    98/100 stars

    Images

    Related Articles

    Biomarker Discovery:

    Article Title: Personalized whole-genome-based ctDNA dynamics during neoadjuvant therapy across breast cancer subtypes: results from MONITOR-Breast.
    Article Snippet: .. Whole blood for ctDNA analysis was collected in Streck Cell-Free DNA BCT® tubes at the following timepoints: baseline (at diagnosis and prior to any systemic treatment), prior to each NAT cycle (approximately every 2–3 weeks depending on regimen and site discretion), following the completion of NAT but prior to surgery, at surgery, and at the post-operative visit (Figure S1A). ..

    Assay Development:

    Article Title: Panel-level multilocus methylation quantification in native cell-free DNA by PCR-compatible sequential enzymatic processing
    Article Snippet: .. Peripheral blood (20 ml) was collected by venipuncture before surgery or colonoscopy, where applicable, into either K2-EDTA tubes (BD Vacutainer) or Cell-Free DNA BCT tubes (Streck), according to the assay-development stage. ..

    Clinical Proteomics:

    Article Title: Comprehensive ctDNA Profiling Enables Tissue-of-Origin Prediction and Actionable Biomarker Detection in Cancer of Unknown Primary
    Article Snippet: .. Whole blood was collected in Cell-Free DNA BCT tubes (Streck, La Vista, NE, USA) and plasma isolation occurred within 96 h using sequential centrifugation at 1800 g and 4700 g. Subsequently the plasma was stored at -80°C until further analysis. .. Samples were batch shipped on dry ice to Guardant Health (Palo Alto, CA, USA) for the isolation of cell free DNA (cfDNA) and next generation sequencing (NGS) using Guardant360 Liquid.

    Article Title: Tumor-naïve ctDNA detection with deep learning-enhanced error suppression for sensitive mutation calling.
    Article Snippet: .. Healthy donor sample set (50 donors) were sourced from BioIVT (Westbury, NY, US): peripheral blood in cell-free DNA BCT tubes (Streck, La Vista, NE, US) for plasma preparation and cfDNA extraction/analysis; EDTA-anticoagulated peripheral whole blood as a normal germline control. ..

    Article Title: Minimally invasive characterization of peripheral blood measurable residual disease in multiple myeloma using high‐sensitivity detection of ctDNA by next‐generation sequencing
    Article Snippet: .. Plasma cfDNA levels remain stable for 24 h when whole blood is stored at 4°C in EDTA tubes without preservatives agents., Although a high cfDNA yield was achieved, future studies may further improve cfDNA recovery by using specialized blood collection tubes that contain cell‐stabilizing agents and nuclease inhibitors, such as Streck Cell‐Free DNA BCT® tubes (La Vista, NE). ..

    Isolation:

    Article Title: Comprehensive ctDNA Profiling Enables Tissue-of-Origin Prediction and Actionable Biomarker Detection in Cancer of Unknown Primary
    Article Snippet: .. Whole blood was collected in Cell-Free DNA BCT tubes (Streck, La Vista, NE, USA) and plasma isolation occurred within 96 h using sequential centrifugation at 1800 g and 4700 g. Subsequently the plasma was stored at -80°C until further analysis. .. Samples were batch shipped on dry ice to Guardant Health (Palo Alto, CA, USA) for the isolation of cell free DNA (cfDNA) and next generation sequencing (NGS) using Guardant360 Liquid.

    Centrifugation:

    Article Title: Comprehensive ctDNA Profiling Enables Tissue-of-Origin Prediction and Actionable Biomarker Detection in Cancer of Unknown Primary
    Article Snippet: .. Whole blood was collected in Cell-Free DNA BCT tubes (Streck, La Vista, NE, USA) and plasma isolation occurred within 96 h using sequential centrifugation at 1800 g and 4700 g. Subsequently the plasma was stored at -80°C until further analysis. .. Samples were batch shipped on dry ice to Guardant Health (Palo Alto, CA, USA) for the isolation of cell free DNA (cfDNA) and next generation sequencing (NGS) using Guardant360 Liquid.

    Extraction:

    Article Title: Tumor-naïve ctDNA detection with deep learning-enhanced error suppression for sensitive mutation calling.
    Article Snippet: .. Healthy donor sample set (50 donors) were sourced from BioIVT (Westbury, NY, US): peripheral blood in cell-free DNA BCT tubes (Streck, La Vista, NE, US) for plasma preparation and cfDNA extraction/analysis; EDTA-anticoagulated peripheral whole blood as a normal germline control. ..

    Control:

    Article Title: Tumor-naïve ctDNA detection with deep learning-enhanced error suppression for sensitive mutation calling.
    Article Snippet: .. Healthy donor sample set (50 donors) were sourced from BioIVT (Westbury, NY, US): peripheral blood in cell-free DNA BCT tubes (Streck, La Vista, NE, US) for plasma preparation and cfDNA extraction/analysis; EDTA-anticoagulated peripheral whole blood as a normal germline control. ..



    Similar Products

    cell free dna bct tubes  (Streck Laboratories)
    98
    Streck Laboratories cell free dna bct tubes
    Cell Free Dna Bct Tubes, supplied by Streck Laboratories, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cell+free+dna+bct+tubes/Cell-Free+DNA+BCT/pm42355602-51-10-14
    Average 98 stars, based on 1 article reviews
    cell free dna bct tubes - by Bioz Stars, 2026-10
    98/100 stars
    		  Buy from Supplier
    cell free dna blood collection tubes  (Streck Laboratories)
    98
    Streck Laboratories cell free dna blood collection tubes
    Cell Free Dna Blood Collection Tubes, supplied by Streck Laboratories, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cell+free+dna+bct+tubes/Cell-Free+DNA+BCT/nct05695638-27-29-34
    Average 98 stars, based on 1 article reviews
    cell free dna blood collection tubes - by Bioz Stars, 2026-10
    98/100 stars
    		  Buy from Supplier
    cell free dna cfdna bct tubes  (Streck Laboratories)
    98
    Streck Laboratories cell free dna cfdna bct tubes
    Cell Free Dna Cfdna Bct Tubes, supplied by Streck Laboratories, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cell+free+dna+bct+tubes/Cell-Free+DNA+BCT/pm42336205-84-5-10
    Average 98 stars, based on 1 article reviews
    cell free dna cfdna bct tubes - by Bioz Stars, 2026-10
    98/100 stars
    		  Buy from Supplier
    cell free dna bct ce tubes  (Streck Laboratories)
    98
    Streck Laboratories cell free dna bct ce tubes
    (A) Longitudinal comparison of PIK3CA E545K detection in serial breast cancer patient samples by ddPCR and NGS (VarDict filter). (B) Dynamics of PIK3CA E545K VAF in relation to therapeutic response. Clinical response data were taken directly from the physician report (Supplementary Table S7). Lines connecting points are shown for visual guidance only and do not represent continuous or quantitative interpolation. (C) Longitudinal mutational landscape detected by the LION panel in samples of the breast cancer patient. Only mutations with a VAF <45% across all samples are shown. The 12 mutations with the highest VAF (>1.5%) are labeled (Supplementary Figure S6 and Table S8A). <t>cfDNA,</t> <t>cell-free</t> DNA; ddPCR, digital droplet polymerase chain reaction; NGS, next generation sequencing; VAF, variant allele frequency.
    Cell Free Dna Bct Ce Tubes, supplied by Streck Laboratories, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cell+free+dna+bct+tubes/Cell-Free+DNA+BCT/med_rxiv__64898__2026__06__05__26354976-66-11-15
    Average 98 stars, based on 1 article reviews
    cell free dna bct ce tubes - by Bioz Stars, 2026-10
    98/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Longitudinal comparison of PIK3CA E545K detection in serial breast cancer patient samples by ddPCR and NGS (VarDict filter). (B) Dynamics of PIK3CA E545K VAF in relation to therapeutic response. Clinical response data were taken directly from the physician report (Supplementary Table S7). Lines connecting points are shown for visual guidance only and do not represent continuous or quantitative interpolation. (C) Longitudinal mutational landscape detected by the LION panel in samples of the breast cancer patient. Only mutations with a VAF <45% across all samples are shown. The 12 mutations with the highest VAF (>1.5%) are labeled (Supplementary Figure S6 and Table S8A). cfDNA, cell-free DNA; ddPCR, digital droplet polymerase chain reaction; NGS, next generation sequencing; VAF, variant allele frequency.

    Journal: medRxiv

    Article Title: A liquid biopsy-centered, pan-cancer, open next generation sequencing panel to support clinical decision-making (LION panel)

    doi: 10.64898/2026.06.05.26354976

    Figure Lengend Snippet: (A) Longitudinal comparison of PIK3CA E545K detection in serial breast cancer patient samples by ddPCR and NGS (VarDict filter). (B) Dynamics of PIK3CA E545K VAF in relation to therapeutic response. Clinical response data were taken directly from the physician report (Supplementary Table S7). Lines connecting points are shown for visual guidance only and do not represent continuous or quantitative interpolation. (C) Longitudinal mutational landscape detected by the LION panel in samples of the breast cancer patient. Only mutations with a VAF <45% across all samples are shown. The 12 mutations with the highest VAF (>1.5%) are labeled (Supplementary Figure S6 and Table S8A). cfDNA, cell-free DNA; ddPCR, digital droplet polymerase chain reaction; NGS, next generation sequencing; VAF, variant allele frequency.

    Article Snippet: Peripheral blood samples were collected in EDTA (Sarstedt, Nümbrecht, Germany) or cell-free DNA-BCT® CE tubes (Streck, La Vista, USA) and processed according to the manufacturer’s instructions as detailed in the Supplementary Methods.

    Techniques: Comparison, Clinical Proteomics, Labeling, Polymerase Chain Reaction, Next-Generation Sequencing, Variant Assay

    (A) Longitudinal comparison of BRAF V600E detection in liquid biopsy samples from the melanoma patient using ddPCR and NGS (VarDict filter). In NGS analysis, the baseline value represents the average of two technical replicates. (B) Overview of sample collection, treatments and disease stages for the melanoma patient. Time points are indicated as weeks after initial diagnosis. Disease stage was determined clinically according to the AJCC classification (2009). Metastasis indicates the presence and location of metastases. All samples are liquid biopsies (cfDNA). (C) Longitudinal dynamics of mutations detected by the LION panel in liquid biopsy samples from the melanoma patient. The baseline sample consists of two technical replicates. Only mutations with a VAF <40% across all samples are shown. The 9 mutations with the highest VAF (>1%) are labeled. For additional details, see Supplementary Figure S7. (D) Overview of sample collection and genetic analyses for the rectal cancer patient in relation to clinical status. Timepoints indicate months after recurrence. Clinical events were assessed by imaging (MRI/CT): “Regression” = tumor regression observed; “Suspected progression” = possible disease progression based on clinical findings (suspicious presacral and pulmonary lesions, as well as suspicious mediastinal and para-iliac lymph nodes). (E) Mutations identified in tumor tissue by WES that were also detectable by the LION panel. The baseline liquid biopsy sample was collected one month after surgery for tumor recurrence; FU1 and FU2 were collected five and nine months later, respectively (see ). (F) Longitudinal dynamics of mutations detected by the LION panel in liquid biopsy samples from the rectal cancer patient. Only mutations with a VAF <30% across all samples are shown. The 8 mutations with the highest VAF (>2%) are labeled. For additional details, see Supplementary Table S11B and Figure S8. cfDNA, cell-free DNA; ddPCR, digitaldroplet polymerase chain reaction; FU, follow-up; NGS, next generation sequencing; TRA, translocation; VAF, variant allele frequency; WES, whole exome sequencing.

    Journal: medRxiv

    Article Title: A liquid biopsy-centered, pan-cancer, open next generation sequencing panel to support clinical decision-making (LION panel)

    doi: 10.64898/2026.06.05.26354976

    Figure Lengend Snippet: (A) Longitudinal comparison of BRAF V600E detection in liquid biopsy samples from the melanoma patient using ddPCR and NGS (VarDict filter). In NGS analysis, the baseline value represents the average of two technical replicates. (B) Overview of sample collection, treatments and disease stages for the melanoma patient. Time points are indicated as weeks after initial diagnosis. Disease stage was determined clinically according to the AJCC classification (2009). Metastasis indicates the presence and location of metastases. All samples are liquid biopsies (cfDNA). (C) Longitudinal dynamics of mutations detected by the LION panel in liquid biopsy samples from the melanoma patient. The baseline sample consists of two technical replicates. Only mutations with a VAF <40% across all samples are shown. The 9 mutations with the highest VAF (>1%) are labeled. For additional details, see Supplementary Figure S7. (D) Overview of sample collection and genetic analyses for the rectal cancer patient in relation to clinical status. Timepoints indicate months after recurrence. Clinical events were assessed by imaging (MRI/CT): “Regression” = tumor regression observed; “Suspected progression” = possible disease progression based on clinical findings (suspicious presacral and pulmonary lesions, as well as suspicious mediastinal and para-iliac lymph nodes). (E) Mutations identified in tumor tissue by WES that were also detectable by the LION panel. The baseline liquid biopsy sample was collected one month after surgery for tumor recurrence; FU1 and FU2 were collected five and nine months later, respectively (see ). (F) Longitudinal dynamics of mutations detected by the LION panel in liquid biopsy samples from the rectal cancer patient. Only mutations with a VAF <30% across all samples are shown. The 8 mutations with the highest VAF (>2%) are labeled. For additional details, see Supplementary Table S11B and Figure S8. cfDNA, cell-free DNA; ddPCR, digitaldroplet polymerase chain reaction; FU, follow-up; NGS, next generation sequencing; TRA, translocation; VAF, variant allele frequency; WES, whole exome sequencing.

    Article Snippet: Peripheral blood samples were collected in EDTA (Sarstedt, Nümbrecht, Germany) or cell-free DNA-BCT® CE tubes (Streck, La Vista, USA) and processed according to the manufacturer’s instructions as detailed in the Supplementary Methods.

    Techniques: Comparison, Biomarker Discovery, Labeling, Imaging, Polymerase Chain Reaction, Next-Generation Sequencing, Translocation Assay, Variant Assay, Sequencing